PAVmed (NASDAQ:PAVM) Stock Crosses Below 50 Day Moving Average of $2.19

PAVmed Inc. (NASDAQ:PAVM) shares crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $2.19 and traded as low as $1.81. PAVmed shares last traded at $1.97, with a volume of 30,577 shares trading hands.

PAVmed Stock Performance

The company has a market capitalization of $17.06 million, a price-to-earnings ratio of -0.20 and a beta of 0.85. The company has a fifty day simple moving average of $2.20 and a two-hundred day simple moving average of $3.10.

PAVmed (NASDAQ:PAVM) last released its quarterly earnings data on Tuesday, March 26th. The company reported ($1.57) EPS for the quarter. The firm had revenue of $1.05 million during the quarter. As a group, analysts expect that PAVmed Inc. will post -5.69 EPS for the current year.

Institutional Trading of PAVmed

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in PAVmed by 2.8% during the 3rd quarter. Vanguard Group Inc. now owns 3,806,574 shares of the company’s stock worth $1,121,000 after purchasing an additional 103,890 shares during the period. Lido Advisors LLC boosted its position in PAVmed by 71.4% during the 3rd quarter. Lido Advisors LLC now owns 120,000 shares of the company’s stock worth $35,000 after purchasing an additional 50,000 shares during the period. Raymond James & Associates boosted its position in PAVmed by 316.9% during the 3rd quarter. Raymond James & Associates now owns 137,760 shares of the company’s stock worth $41,000 after purchasing an additional 104,717 shares during the period. Charles Schwab Investment Management Inc. purchased a new stake in PAVmed during the 2nd quarter worth $32,000. Finally, Wells Fargo & Company MN boosted its position in PAVmed by 18.6% during the 4th quarter. Wells Fargo & Company MN now owns 366,570 shares of the company’s stock worth $176,000 after purchasing an additional 57,533 shares during the period. 19.93% of the stock is currently owned by institutional investors and hedge funds.

About PAVmed

PAVmed Inc operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay.